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Abstract:  Anthrax  is  caused  by  the  gram-positive  bacterium  Bacillus  anthracis.  The 
pathogenesis of this disease is dependent on the presence of two binary toxins, edema toxin 
(EdTx) and lethal toxin (LeTx). LeTx, the major virulence factor contributing to anthrax, 
contains the effector moiety lethal factor (LF), a zinc-dependent metalloprotease specific 
for  targeting  mitogen-activated  protein  kinase  kinases.  This  review  will  focus  on  the 
protease-specific  activity  and  function  of  LF,  and  will  include  a  discussion  on  the 
implications and consequences of this activity, both in terms of anthrax disease, and how 
this activity can be exploited to gain insight into other pathologic conditions. 
Keywords: anthrax; lethal factor; mitogen-activated protein kinase kinase; pathogenesis; 
metalloprotease; tumorigenesis; retinal neovascularization 
 
1. Introduction  
Over the last decade there has been a renewed interest in understanding anthrax due to the recent 
use of anthrax as a biological weapon. While the mechanism by which anthrax kills its host is still 
unclear,  the  lethality  of  the  disease  was  attributed  to  the  production  of  anthrax  toxin  more  than  
50 years ago [1]. Following this seminal discovery by Smith and Keppie, it has been determined that 
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anthrax toxin is composed of three proteins that when combined in pairwise fashion form two binary 
toxins: protective antigen (PA), edema factor (EF), and lethal factor (LF) [2]. PA alone is non-toxic, 
but serves to translocate EF or LF to the cytosol [3]. The combination of PA with EF, called edema 
toxin (EdTx), results in edema upon subcutaneous injection, but is nontoxic following intravenous 
administration to animals [4]. PA plus LF does not induce edema, however is toxic when injected 
intravenously into animals [4,5], and is therefore referred to as lethal toxin (LeTx) [5].  
Prior to EF or LF translocation to the cytosol, PA must first bind to one of two identified cell 
surface  anthrax  toxin  receptors,  tumor  endothelial  marker-8  (TEM8)  and  capillary  morphogenesis 
gene-2 (CMG2)[6,7]. Proteolytic cleavage of PA by cell surface-associated furin generates an active 
molecule, which forms a heptameric prepore complex capable of binding up to three EF and/or LF 
molecules (although evidence exists of cleaved PA in the circulation [8]). Upon endocytosis via the 
endosomal pathway, changes in pH alter prepore formation, allowing translocation of EF and LF to the 
cytosol where they perform their enzymatic functions [9].  
EF is a calmodulin-dependent adenylate cyclase that upon activation increases the conversion of 
intracellular ATP to cyclic AMP (cAMP). This results in the disruption of water homeostasis followed 
by edema [10]. Although B. anthracis strains deficient in EF production were shown to still be lethal in 
mice [11], EF does in fact play a role in anthrax pathogenesis. EdTx can inhibit phagocytosis of  
B.  anthracis  by  neutrophils  [12],  suggesting  that  EdTx  can  increase  susceptibility  to  infection  by 
suppressing neutrophil function. Furthermore, EdTx has been shown to be cytotoxic, causing tissue 
necrosis using a zebrafish model [13], as well as tissue damage and lethality in mice [14], implicating 
EdTx as having a toxic role in anthrax pathogenesis. 
LeTx  is  considered  the  major  virulence  factor  of  anthrax  and  the  mediator  of  host  lethality. 
Consequently,  research  efforts  have  focused  more  heavily  on  the  mechanism  of  action  of  LeTx 
compared to that of EdTx. Vascular pathologies such as hemorrhage and septic shock are common 
features  of  anthrax,  as  is  modulation  of  the  host  immune  system,  and  LeTx  is  thought  to  play  a 
causative role in these pathologies [15–17]. Furthermore, LeTx can induce macrophage apoptosis [18], 
modulate cytokine secretion of dendritic cells [19], and directly inhibit T-cell activation [20]. LeTx has 
been shown to play a role in vascular integrity and endothelial cell function in clinical examples [21] 
and experimental models [22–25]. However, the mechanism of anthrax lethality is still not understood. 
In this review, we will describe the identification of LF as a zinc-dependent metalloprotease specific 
for  mitogen  activated  protein  kinase  kinases  (MAPKKs,  MEKs  or  MKKs),  and  the  potential 
consequences of this activity to the host following anthrax infection in terms of disease pathogenesis. 
Finally, we will explore the utility of exploiting this activity to further our understanding not only of 
the mechanism of LeTx action, but also as a tool to evaluate the role of MEK signaling pathways in 
neovascular disease. 
2. Structure and Function of Lethal Factor 
2.1. Identification of functional domains of LF 
Lethal factor (LF) is a 90 kDa secreted protein encoded by the lef locus on the pXOI plasmid of  
B. anthracis [26]. The crystal structure of LF has been solved and is reviewed elsewhere [27]. LF is Toxins 2010, 2                             
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encoded by a 2,427 bp open reading frame that can be divided into three regions: (1) a PA-binding 
region contained within the first 254 amino acids at the NH2 terminus, which has a high degree of 
similarity  to  the  amino  terminus  of  EF,  (2)  a  central region  containing  a  series of  five  imperfect  
19  amino  acid  repeats,  and  (3)  the  remaining  C-terminal  portion  of  the  protein  that  exhibits  no 
sequence homology to known proteins (reviewed in [28]). Mutagenesis mapping of LF demonstrated 
that the C-terminal region is responsible for the enzymatic activity of the protein. Insertions into this 
region  eliminated  toxicity  without  alteration  in  PA  binding  [29].  Further  analysis  of  this  domain 
identified  a  portion  (amino  acids  686-692;  protein  sequence  HEFGHAV)  containing  a  motif 
characteristic of metalloproteases (HEXXH, where X is any amino acid) [30]. 
2.2. LF is a zinc-dependent metalloprotease 
The presence of a metalloprotease-like motif contained within the catalytic portion of LF suggested 
LF  was  a  protease.  In  support  of  this,  protease  inhibitors  such  as  bestatin  and  captopril  blocked  
LF-mediated toxicity of  macrophages  [30]. Moreover, the substitution of alanine for  two residues 
implicated in zinc binding (H686A and H690A) resulted in LF inactivation as well as reduced zinc 
binding, and substitution of cysteine for glutamic acid at amino acid 687 (E687C), a residue known to 
be essential for metalloprotease activity, led to the inactivation of LF [30]. Finally, LF has been shown 
to bind at least one 
65Zn atom [30,31], and zinc binding is reduced in inactive LF mutants [30].  
3. LF Zinc-Metalloprotease Activity Is Specific for the MAPK Pathway 
While evidence strongly indicated that LF was a zinc-dependent metalloprotease, it was several 
years  before  the  enzymatic  substrate  of  LF  was  identified.  In  1998,  two  groups  independently 
identified  mitogen-activated  protein  kinase  kinase  1 and  2  (MAPPK1  and  2,  or  MEK1  and  2)  as 
proteolytic substrates for LF [32,33].  
The MAPK pathway is a key regulatory signal transduction pathway, which sends signals from the 
cell surface to intracellular effectors via a cascade of phosphorylation events (Figure 1). In mammalian 
cells, there are three extensively studied MAPK pathways: the extracellular signal-regulated kinase 
pathway (ERK), the p38 MAPK pathway (p38), and the c-Jun N-terminal kinase pathway (JNK). The 
ERK pathway is preferentially activated by growth factors, while the p38 and JNK pathways respond 
to cellular stresses such as osmotic shock and inflammatory cytokines (reviewed in [34]). ERK1 and 
ERK2 are activated by MEK1 and MEK2, p38 by MKK3 and MKK6, while JNK is activated by 
MKK4 and MKK7. These MAPKKs are in turn activated by different MAPKK kinases (MAPKKKs), 
which  are  differentially  activated  by  extracellular  stimuli,  including  growth  factors,  inflammatory 
signals, and environmental stresses (reviewed in [35]). These pathways regulate a variety of cellular 
responses  including  cell  cycle  progression,  cell  division,  differentiation,  motility,  apoptosis,  and 
survival [35].  
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Figure 1. Schematic of the kinase cascade and resulting cellular responses of the MAPK 
signaling  pathways.  (A)  Generic  scheme  of  the  MAPK  signaling  cascade,  whereby  an 
extracellular stimulus activates MAPKKK, which phosphorylates and activates MAPKK, 
which phosphorylates and activates MAPK, leading to an intracellular biological response. 
(B)  Schematic  of  the  specific  MAPK  factors  within  each  of  the  three  major  MAPK 
pathways. LeTx targets the MAPKK tier in the cascade, cleaving and inactivating all the 
MAPKK (MEK1-2, MKK3-7) with the exception of MKK5, the pathway for which is  
not depicted. 
 
That the MAPKKs were substrates for LF cleavage was first suggested by the observation of a 
subtle  shift  in  electrophoretic  mobility  of  MEK1  following  LeTx  treatment,  which  implicated  a 
proteolytic modification of MAPKK by LF; this modification was subsequently shown to be located at 
the  N-terminus  of  MAPKK  [32,33].  It  was  quickly  determined  thereafter  that  LF  cleaves  all  the 
MAPKK with the exception of MKK5 [36–38] (Figure 2). Interestingly, MKK4 and MKK7 appear to 
contain two cleavage sites within close proximity to each other in the N-terminal region, while the 
other MAPKKs contain single cleavage sites (Table 1). Analysis of the cleavage sites indicated a 
preferential cleavage just before an aliphatic residue, which is located two-to-three residues from a 
stretch of basic amino acids (Table 1). Generic MAPK binding sites (referred to as the MAPK docking 
domain) display a similar pattern of amino acids, consisting of a basic residue flanked by hydrophobic 
residues on one or both sides [39,40]. This provided a hint to a mechanism by which LF cleavage 
inactivates MAPKKs. In fact, LF was shown to reduce the affinity of MEK1 for MAPK [41,42], and 
decrease the intrinsic kinase activity of MEK [41]. Other regions of MEK besides the N-terminus 
appear to be required for LF-substrate recognition [33,41], which may explain the specificity of LF for 
MAPKKs and not other proteins containing a MAPK-interacting D domain. Toxins 2010, 2                             
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Figure 2. Inhibitory effect of LeTx on MEK signaling pathway in cells. Human melanoma 
SK-MEL-28  cells  were  treated  with  LeTx  in  a  LF  concentration-dependent  manner  
(1 μg/mL PA plus 0, 1, 10, or 100 ng/mL LF) for 24 h. Whole cell extracts were then 
harvested and subjected to immunoblotting with antibodies against MEK1 N-terminus (top 
panel), MEK1 C-terminus (second panel), phospho-ERK1/2 (third panel), total ERK1/2 
(fourth panel) and β actin (bottom panel). 
 
Table 1. Alignment of MEK/MKK amino acid sequences flanking the LF cleavage sites. 
MEK/MKK amino acid sequences (single-letter codes) are aligned to the position where 
LF cleaves (slash). Aliphatic residues (Al) at the protease cleavage position 1’ (bold) are 
fully conserved in all the LF cleavage sites. The basic (B) or proline (P) residues prior to 
the cleavage sites are shaded. (X) variable residues. 
LF substrates  Amino acid sequences 
MEK1  M P K K K P T P
(8)  / I Q L N P A P D 
MEK2  A R R K P V L P
(11)  / A L T I N P T I 
MKK3  S K R K K D L R
(26)  / I S C M S K P P 
MKK4(K
45-L
46)  Q G K R K A L K
(45)  / L N F A N P P F 
MKK4(R
58-F
59)  P P F K S T A R
(58)  / F T L N P N P T 
MKK6  K K R N P G L K
(14)  / I P K E A F E Q 
MKK7(Q
44-L
45)  Q R P R P T L Q
(44)  / L P L A N D G G 
MKK7(Q
76-L
77)  A R P R H M L G
(76)  / L P S T L F T P 
     
Consensus sequence  (B/P)3-4 X X X  / Al 
4. Consequences of the Zinc-Dependent Metalloprotease Activity of LF 
4.1. Immune modulation 
To establish a successful infection, B. anthracis must have mechanisms in place to suppress the 
immune system. LeTx affects various aspects of the immune system including cytokine, dendritic cell 
and T-cell responses [15,17]. LeTx appears to exert its immunosuppressive effects by blocking the 
function of phagocytes, resulting in a delay in wound healing and favoring bacterial growth, and by Toxins 2010, 2                             
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inhibiting cell-mediated immunity, to prevent death of infected macrophages. A well studied major 
cellular target of LeTx is macrophages, as LeTx was first demonstrated to exhibit cytotoxicity in vitro 
to murine macrophages [43]. It is now clear that macrophages are not the only target cell of LeTx, 
particularly in the immune system [44]. Monocytes, dendritic cells, and T cells, among others, all 
appear to be disregulated, in terms of cytokine secretion, activation, and proliferation, following LeTx 
treatment. In particular, LeTx is a potent T cell suppressor, both in terms of T cell activation and 
proliferation, but also in the ability of T cells to migrate and chemotax [45]. The inhibition of T cell 
chemotaxis  likely  impairs  numerous  pathways  that  contribute  to  bacterial  clearance  and  
wound healing. 
The  MAPK  pathways  are  central  to  the  activation  of  both  the  innate  and  adaptive  immune  
responses [46]. MAPK activation has been suggested to play a role in macrophage phagocytosis [47,48]. 
Additionally, MAPK signaling pathways play key roles in activated T cell gene expression, and T cells 
disrupted  in  MAPK  pathway  signaling  via  LeTx-induced  cleavage  of  MAPKKs  have  dramatic 
alterations in the activation of key transcription factors [20,49]. While, activation of the ERK pathway 
has been shown to be important in T cell maturation, activation, and differentiation [50,51], it is the 
p38 and JNK pathways that exert the greatest influences on immune responses. Activation of these 
pathways is important for a variety of immune responses, including initiation, activation, and progression 
of both the innate and adaptive immunities  [52,53]. These pathways can regulate the expression of  
pro-inflammatory  cytokines  in  macrophages  [53],  contribute  to  the  development,  activation,  and 
proliferation of T cells [54,55], and play roles in dendritic cell migration and activation [56,57]. 
4.2. Vascular damage 
Vascular  damage  and  dysfunction  are  hallmarks  of  anthrax  infection;  vascular  leakage,  tissue 
hemorrhage, and terminal hypotensive shock are commonly associated with anthrax pathology. These 
effects  are  likely  caused  by  increased  vascular  permeability.  This  has  led  to  studies  aimed  at 
identifying  potential  direct  effects  of  LeTx  action  on  endothelial  cells,  and  suggests  that  
LeTx-mediated MAPKK inhibition may alter endothelial cell function. In support of this, in vitro 
studies have shown that LeTx can reduce endothelial cell viability and induces apoptosis of endothelial 
cells [22], as well as induce endothelial barrier dysfunction [23,58].  
That alterations in vascular permeability and endothelial cell function result from MAPK pathway 
interference  is  not  surprising.  The  MAPK  pathway  has  been  shown  to  play  a  pivotal  role  in 
vascularization  in  early  embryonic  development  [59].  Deficiencies  in  various  components  of  the 
MAPK cascade, as studied by way of knockout mice, result in defects in embryonic vascularization. 
For  example,  MEK1  and  ERK2  knockout  mice  have  defective  placental  vascularization  [60,61], 
defects in MEK5 result in cardiovascular defects [62], and B-Raf knockout mice display extensive 
vascular defects [63].  Toxins 2010, 2                             
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5. The Utility of the MEK-Dependent Metalloprotease Activity of LF in Other Pathological 
Conditions 
5.1. Tumor growth and angiogenesis 
It is of interest to note that the initial discovery suggesting MAPKK as the substrate of LF came 
from a sensitivity screen of the National Cancer Institute’s anti-neoplastic drug screen database, which 
identified LF as having a similar sensitivity profile against 60 human cancer cell lines as the known 
MEK  inhibitor,  PD98059  [32,64].  Not  only  did  this  suggest  MAPKKs  as  substrates  for  LF,  but 
implicated LeTx as a potential novel therapeutic for tumorigenesis. 
The MAPK signaling pathways have been intensely studied in terms of their roles in tumor growth 
and  progression  due  to  their  implicated  actions  as  regulators  of  cell  proliferation,  migration,  and 
apoptosis, all of which are critical steps for tumor growth, survival, and metastasis [65]. In fact, MAPK 
pathways  have  been  suggested  to  play  critical  roles  in  tumorigenesis  based  on  the  fact  that  they 
regulate proteolytic enzymes that can promote invasion and progression, migration and motility, which 
may  enhance  metastatic  potential,  and  regulation  of  apoptosis to  promote  survival,  particularly  of 
metastatic cells to distant locations. Not surprisingly, therefore, LeTx was initially shown to inhibit the 
growth and tumorigenicity of V-12 H-ras transformed NIH 3T3 fibroblasts in vitro [38]. It has since 
been demonstrated that in vivo administration of LeTx by intratumoral administration of LeTx [38,64], 
as well as by systemic treatment [66–68], inhibits tumor growth (Figure 3). 
While  systemic  administration  of  LeTx  reduced  tumor  growth  in  xenograft  models,  it  also 
substantially  reduced  tumor  vascular  content,  indicating  that  MAPKK  signaling  is  important  for 
vascularization of tumors in vivo [38,67,68]. Importantly, as tumor vascularization is driven by the 
release of angio-proliferative growth factors from tumor cells that induce angiogenesis, analysis of 
tumor xenografts revealed that LeTx treatment decreased the release of a number of angio-proliferative 
factors, including basic fibroblast growth factor (bFGF), interleukin-8 (IL-8), and vascular endothelial 
growth factor (VEGF) [68], the same cytokines noted as strong correlates of disease-free and overall 
survival in other tumors such as melanoma [69].  
Recently, PA alone has been reported to inhibit tumor angiogenesis [70]. However, these effects are 
only evident at relatively elevated concentrations, and by use of a mutant form of PA that is resistant to 
furin activation. At concentrations associated with LF-impaired angiogenesis (i.e., 10–100 fold lower), 
wild-type  PA alone  or  in  combination with  catalytically  inactive  LF  has  no  measurable effect on 
angiogenesis  [64,68].  Interestingly,  the  extracellular  domain  of  anthrax  toxin  receptors  (ANTXR) 
contains a von Willebrand factor type A (vWFA) domain, a conserved ligand binding that mediates 
extracellular  matrix  associations  [71].  These  domains  within  ANTXR  have  since  been  shown  to 
associate with specific extracellular matrix proteins such as gelatin and type 1 collagen for TEM8 [72], 
and collagen type IV and laminin for CMG2 [73]. As PA-binding to these receptors could interfere 
with extracellular matrix interactions by ANTXR, elevated levels of extracellular PA may disrupt 
endothelial cell adhesion, leading to impaired angiogenesis. 
MAPK  pathway  signaling  has  previously  been  shown  to  play  essential  roles  in vascularization 
during  tumorigenesis,  specifically  by  modulating  the  release  of  and  response  to  VEGF,  which  is 
recognized as a critical growth factor in angiogenesis [74]. MEK activity regulates VEGF expression Toxins 2010, 2                             
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at the transcriptional and post-transcriptional levels [75]. The ERK pathway has been demonstrated to 
be critical in the control of VEGF expression [76] and to mediate VEGF-induced proliferation via the 
endothelial-specific receptor, VEGFR2 [77], while JNK and p38 have been shown to regulate VEGF 
expression [75]. MEK signaling pathways are also activated in response to VEGF, whereby treatment 
of endothelial cells with VEGF results in activation of ERK1/2 [78], as well as p38 [79]. Insight into 
the in vivo functions of MAPKKs has been implicated by the effect of MAPKK inhibitors on tumor 
vascularization. For example, expression of an inactive Raf-1 mutant in endothelial cells blocks growth 
and vascularization of melanomas in mice [80], while BAY 43-9006 (Sorafenib), a compound that 
inhibits B-Raf and c-Raf, (MAPKKK isoforms that activate MEK1 and MEK2), also reduces tumor 
vascularization in vivo [81]. More recently, expression of dominant negative MKK1 in tumor endothelium 
has been shown to disrupt growth and vascularization of colorectal adenocarcinoma xenografts [82]. 
Figure 3. Inhibitory effect of LeTx on human melanoma SK-MEL-28 xenograft tumor 
growth. Human melanoma SK-MEL-28 cells were subcutaneously injected (10
7 cells in 
100 μl HBSS) into the right side of the dorsalateral area of athymic nude mice (10 mice per 
group). After tumors were established to a volume of 50 mm
3, mice were intravenously 
injected with either LeTx (PA plus LF) or control (PA plus LF_E687C) at one standard 
dose (SD, 1 SD equals 10 μg PA plus 2 μg of LF or LF_E687C) every other day for a total 
of six injections. Tumor growth is presented as average tumor volume (mm
3) against days 
following inoculation of tumor cells. (■) average volume of the total 10 tumors before 
treatment. (□) average volume of the tumors in control-treated mice. (♦) average volume of 
the tumors in LeTx-treated mice. 
 
Whereas  in  vitro  studies  of  LeTx  pointed  to  a  role  for  MAPK  signaling  in  regulating  VEGF 
expression in tumor cells, a different picture emerged from in vivo studies in which it was noted that 
tumors deficient in anthrax toxin receptor expression were still sensitive to LeTx treatment, resulting in 
decreased  tumor  growth  in  vivo  [83].  Furthermore,  vital  imaging,  performed  on  fibrosarcoma Toxins 2010, 2                             
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xenografts  using  high-resolution  ultrasound,  demonstrated  that  MEK  inhibition  through  LeTx 
treatment led to a striking and rapid reduction in tumor perfusion within 24 h of LeTx treatment [68]. 
While  its  ability  to  reduce  tumor  vascularization  may  be  linked  to  decreased  tumor-cytokine 
production, the ability of LeTx to block growth of receptor deficient tumors, as well as the  rapid 
reduction in perfusion following LeTx administration, strongly argues that MEK inhibition by LeTx 
inhibits tumor vascularization not by direct action on tumor cells, but through a stromal component of 
the tumor, perhaps endothelial cells. 
5.2. Retinal Neovascularization 
To further investigate the effects of LeTx on neovascularization, a mouse model of retinal vascular 
growth  and  neovascularization  has  been  adapted  [84].  Retinal  vasculature  forms  in  a  
well-characterized  and  highly  reproducible  manner,  providing  a  convenient  system  to  evaluate 
contributions to vascular formation and development. Due to vascular growth in two dimensions, the 
retina provides a convenient model to directly observe developmental angiogenesis, as well as a useful 
model to monitor and quantify changes in vascular growth. Retinal vascular development is intensely 
studied,  especially  in  the  context  of  retinopathies,  whereby  abnormal  vascular  growth  (termed 
neovascularization) in the retina can lead to blindness. Common retinopathies of this nature include 
retinopathy of prematurity (ROP) and diabetic retinopathy (DR), which are characterized by retinal 
neovascularization  [85],  and  age-related  macular  degeneration  (AMD),  which  is  characterized  by 
pathological outgrowth of new vessels from the choroid into the subretinal space [86]. VEGF has been 
shown to play a central role as a stimulator of both retinal and choroidal neovascularization, whereby 
inhibition of VEGF can block both types of neovascularization in the eye [86-88]. In fact, intravitreal 
injections  of agents  that  block VEGF  function have  been  shown to  stabilize  and even  potentially 
improve vision in patients with AMD [89].  
Previously published reports suggest a role for the signaling of the MAPK pathways during both 
vascular development and disease progression in the retina. It has been demonstrated in vitro that 
while the Ras/Raf/MEK/ERK pathway activated proliferation of retinal pigmented epithelial (RPE) 
cells [90], the JNK and p38 MAPK pathways have been characterized for their role in RPE cell death [91]. 
Furthermore, an increase of ERK activation was detected in a rat model of ROP, and intravitreous 
injection  of  ERK  inhibitors  reduced  retinal  neovascularization  in  this  in  vivo  model  system  [92]. 
Increased MAPK activation has been reported in retinal ischemia-reperfusion models [93,94], and 
recently, the JNK pathway has been shown to play a key role in retinal neovascularization in a mouse 
model of ROP [95]. It has since been demonstrated that LeTx delays the sprouting angiogenesis and 
branching morphogenesis during developmental vascularization in the murine retina [84], and appears 
to inhibit both neovascularization and revascularization following oxygen-induced retinopathy [96]. 
These data suggest that MAPK signaling pathways could be a source of novel targets for therapeutic 
intervention of ocular diseases that have an angiogenic component.  
6. Conclusions  
Despite years of study we still do not fully understand how Bacillus anthracis causes death. We do 
know that LeTx plays a critical role in the pathogenesis of the disease, and that the proteolytic function Toxins 2010, 2                             
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of LF is essential for LeTx activity. Further insight into the function of LeTx, and the role of LF 
metalloprotease activity upon anthrax infection, can be gained by analyzing the effect of LeTx on other 
pathological conditions. In both tumor and retinal models, the primary effects of LeTx lead to vascular 
dysfunction that causes hemorrhage and decreased perfusion (Table 2). While LeTx is capable of 
affecting multiple cell types, its common effect on vascular function indicates one or more cell types 
that modulate endothelial function, such as macrophages, pericytes, or endothelial cells, may be critical 
targets in the pathogenesis of this disease. However, the specific role of MAPKK inhibition in these 
pathologies by LeTx is still not understood.  
Table 2. Effect and consequences of LeTx metalloprotease activity. 
Effect  Anthrax [16,21,24,97]  Tumor [32,38,64,68]  Retina [84] 
Macrophage activity  Altered phagocytosis, 
Septic shock-like 
syndrome 
n.d.  n.d. 
Cytokine release  mixed effects in vitro 
and in vivo 
Largely depressed in 
vitro and in vivo 
Largely depressed  
in vitro and in vivo 
sequelae–elevated 
VEGF 
Vascular function   Hemorrhage, vascular 
permeability, hypoxia, 
hypotension 
Decreased perfusion, 
hemorrhage, decreased 
mean vessel density 
Decreased perfusion, 
block in branching 
morphogenesis 
Consequence  Hypotensive shock, 
death 
Decreased tumor 
volume 
Retinopathy 
n.d.: not determined. 
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